About Prof. Dr. Taylan Senol

Prof. Dr. Taylan Senol was born in Istanbul in 1981. His clinical practice concentrates on cancers of the female reproductive system and on surgery that requires subspecialty training: cancers of the uterus, cervix, ovary, vulva and peritoneum, together with laparoscopic, robotic and organ preserving procedures.

Training and Career

The timeline below follows his published curriculum vitae.

• 1999 to 2005 Medical education, Istanbul University Cerrahpasa Faculty of Medicine
• 2005 to 2010 Residency in Obstetrics and Gynecology, Istanbul Goztepe Training and Research Hospital
• 2011 to 2013 Compulsory state service, Sirnak Military Hospital, Sivas Susehri and Istanbul Esenyurt State Hospitals
• 2013 to 2016 Subspecialty fellowship in Gynecologic Oncologic Surgery, Istanbul Zeynep Kamil Women’s and Children’s Diseases Training and Research Hospital
• 2014 to 2016 Member of the postpartum emergency haemorrhage team, Istanbul Anatolian side maternal mortality prevention programme
• 2016 to 2018 Gynecologic oncology surgeon, Sanliurfa Training and Research Hospital
• December 2017 Title of Associate Professor in Obstetrics and Gynecology
• 2018 Observership, Charite Universitatsmedizin, Virchow Klinikum Berlin, Department of Gynecology
• 2018 to 2022 Gynecologic oncology surgeon, Bagcilar Training and Research Hospital
• 2022 onwards Private practice, Bakirkoy, Istanbul

Surgical Practice

• Gynecologic cancer surgery of the uterus, cervix, ovary, vulva and peritoneum
• Laparoscopic and minimally invasive surgery
• Robotic surgery
• Hysteroscopic surgery
• Organ and fertility preserving surgical approaches

What a Gynecologic Oncology Subspecialty Means

In Turkey, as in most European countries, gynecologic oncology is a subspecialty entered after a full residency in obstetrics and gynecology. It requires separate training and a separate qualification, and it exists because cancer operations in this field differ from routine gynecologic surgery in scope: staging, lymph node assessment and decisions about how much tissue must be removed all change the outcome of treatment.

For a patient, the practical consequence is that the surgical plan is made by someone trained specifically in that decision, and that organ preserving or fertility preserving options are weighed against oncological safety rather than chosen by default in either direction.

Professional Memberships

• Turkish Society of Obstetrics and Gynecology, member since 2006
• Turkish Society of Gynecologic Oncology, member since 2015
• ESGO, European Society of Gynaecological Oncology, member since 2015

Languages of Publication

Patient information on this site is written mainly in Turkish, where more than three hundred articles cover gynecologic cancers, surgery and women’s health. This English section is a focused summary for readers who do not speak Turkish and is being extended page by page.

Certifications

• Laboratory Animal Use Certificate, Yeditepe University, 2015
• Training of Trainers Certificate, Istanbul University, 2019
• Good Clinical Practice, Clinical Research Association, 2020

How He Works

Treatment begins with a decision, not with a procedure. Although the name of the disease may be the same for two patients, their age, circumstances, expectations and general health are not. The plan is therefore built around the patient as a whole rather than the diagnosis alone.

Where the disease allows it, organ preserving and fertility preserving options are discussed openly, including what each choice would mean for follow up. Where it does not, that is explained just as plainly.

Follow up is treated as part of the treatment, not as an afterthought. After surgery the pathology report is reviewed with the patient, because it determines both whether further treatment is needed and how often checks should be repeated. Patients who arrive with a diagnosis already made elsewhere are welcome to bring their imaging and pathology reports for a further opinion before deciding on surgery.

To arrange a consultation, see the contact page.